AU2018342245B2 - Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation - Google Patents

Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation Download PDF

Info

Publication number
AU2018342245B2
AU2018342245B2 AU2018342245A AU2018342245A AU2018342245B2 AU 2018342245 B2 AU2018342245 B2 AU 2018342245B2 AU 2018342245 A AU2018342245 A AU 2018342245A AU 2018342245 A AU2018342245 A AU 2018342245A AU 2018342245 B2 AU2018342245 B2 AU 2018342245B2
Authority
AU
Australia
Prior art keywords
cells
ser
leu
mutated
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018342245A
Other languages
English (en)
Other versions
AU2018342245A1 (en
Inventor
Drew C. Deniger
Parisa MALEKZADEH
Steven A. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2018342245A1 publication Critical patent/AU2018342245A1/en
Application granted granted Critical
Publication of AU2018342245B2 publication Critical patent/AU2018342245B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1121—Dendritic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Oncology (AREA)
AU2018342245A 2017-09-29 2018-09-17 Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation Active AU2018342245B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762565464P 2017-09-29 2017-09-29
US62/565,464 2017-09-29
PCT/US2018/051280 WO2019067242A1 (en) 2017-09-29 2018-09-17 METHODS FOR ISOLATING T CELLS HAVING ANTIGENIC SPECIFICITY FOR SPECIFIC MUTATION OF CANCER P53

Publications (2)

Publication Number Publication Date
AU2018342245A1 AU2018342245A1 (en) 2020-04-16
AU2018342245B2 true AU2018342245B2 (en) 2024-06-13

Family

ID=63763012

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018342245A Active AU2018342245B2 (en) 2017-09-29 2018-09-17 Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation

Country Status (10)

Country Link
US (1) US20200316121A1 (https=)
EP (2) EP3688142B1 (https=)
JP (1) JP7391015B2 (https=)
KR (1) KR102809909B1 (https=)
CN (1) CN111344394A (https=)
AU (1) AU2018342245B2 (https=)
CA (1) CA3080274A1 (https=)
IL (1) IL273516B2 (https=)
SG (1) SG11202002635RA (https=)
WO (1) WO2019067242A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123847B3 (de) 2016-12-08 2018-04-05 Immatics Biotechnologies Gmbh Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
HUE058957T2 (hu) * 2016-12-08 2022-10-28 Immatics Biotechnologies Gmbh Új T-sejt receptorok és velük végzett immunterápia
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
US11807662B2 (en) 2017-05-16 2023-11-07 The Johns Hopkins University MANAbodies and methods of using
CA3144070A1 (en) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r175h or y220c mutation in p53
CN112390875B (zh) * 2019-08-16 2023-01-24 香雪生命科学技术（广东）有限公司 一种识别afp的高亲和力t细胞受体
EP4077370A4 (en) * 2019-12-17 2024-02-28 The Johns Hopkins University MANABODIES TARGETING TUMOR ANTIGENS AND METHODS OF USE
WO2021123832A1 (en) 2019-12-20 2021-06-24 Instil Bio (Uk) Limited Devices and methods for isolating tumor infiltrating lymphocytes and uses thereof
CN113621070A (zh) 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
EP4208473A2 (en) * 2020-09-04 2023-07-12 The United States of America, as represented by the Secretary, Department of Health and Human Services T cell receptors recognizing r273c or y220c mutations in p53
CN112301088B (zh) * 2020-10-21 2022-12-13 杭州纽安津生物科技有限公司 一种筛选新生抗原或新生抗原编码序列的方法
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
US20240165120A1 (en) * 2021-03-08 2024-05-23 Taiho Pharmaceutical Co., Ltd. Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
CA3215580A1 (en) * 2021-03-31 2022-10-06 The Johns Hopkins University Methods and materials for targeting tumor antigens
WO2022236050A1 (en) * 2021-05-07 2022-11-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing c135y, r175h, or m237i mutation in p53
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
EP4423143A4 (en) * 2021-10-29 2025-10-01 Yafei Hou T CELL RECEPTOR RECOGNIZING R175H MUTATION IN P53 AND ITS APPLICATION
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
WO2024131372A1 (zh) * 2022-12-23 2024-06-27 上海市第一人民医院 靶向巨细胞病毒pp65的TCR和表达其的T细胞及应用
KR20260028688A (ko) * 2023-05-25 2026-03-04 엘리시오 테라퓨틱스, 인크. P53 펩티드 양친매체를 함유하는 조성물 및 이의 이용 방법
CN116970058B (zh) * 2023-09-22 2023-12-15 成都朗谷生物科技股份有限公司 针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
WO2025060149A1 (zh) * 2023-09-22 2025-03-27 上海市第一人民医院 一种分离的tcr及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2139012T3 (es) 1992-05-26 2000-02-01 Univ Leiden Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
JPH0959175A (ja) * 1995-06-12 1997-03-04 Meiji Milk Prod Co Ltd 抗腫瘍免疫活性化剤
AU2003265948B8 (en) 2002-09-06 2009-09-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
GB2440736A (en) * 2006-08-10 2008-02-13 Medical Res Council Crystals of mutant p53 polypeptidtes
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
AU2014407539B2 (en) 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
AU2015343013B2 (en) * 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
MX384919B (es) * 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
EA202090757A1 (ru) * 2017-09-29 2020-08-21 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез T-КЛЕТОЧНЫЕ РЕЦЕПТОРЫ, РАСПОЗНАЮЩИЕ МУТАНТНЫЙ p53

Also Published As

Publication number Publication date
EP3688142A1 (en) 2020-08-05
AU2018342245A1 (en) 2020-04-16
KR102809909B1 (ko) 2025-05-22
EP4495133A2 (en) 2025-01-22
KR20200065026A (ko) 2020-06-08
IL273516A (en) 2020-05-31
US20200316121A1 (en) 2020-10-08
JP7391015B2 (ja) 2023-12-04
IL273516B2 (en) 2025-06-01
WO2019067242A1 (en) 2019-04-04
EP3688142B1 (en) 2025-04-09
EP4495133A3 (en) 2025-04-09
CN111344394A (zh) 2020-06-26
IL273516B1 (en) 2025-02-01
SG11202002635RA (en) 2020-04-29
JP2020534839A (ja) 2020-12-03
CA3080274A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
AU2018342245B2 (en) Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation
AU2022203507B2 (en) Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
AU2021202223B2 (en) Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP3688027B1 (en) T cell receptors recognizing mutated p53
AU2014407539B2 (en) Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
AU2020308004B2 (en) T cell receptors recognizing R175H or Y220C mutation in p53
HK40031141A (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
HK40031141B (en) Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
RU2830061C2 (ru) T-клеточные рецепторы, распознающие мутацию r175h или y220c в p53
WO2025122800A1 (en) Identification of neoantigen-reactive t cell receptors
HK40031140B (en) T cell receptors recognizing mutated p53

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)